CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial

PURPOSE: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. METHODS: Participants with chronic pain (94% on...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Genet Med
Autors principals: Smith, D. Max, Weitzel, Kristin W., Elsey, Amanda R., Langaee, Taimour, Gong, Yan, Wake, Dyson T., Duong, Benjamin Q., Hagen, Melanie, Harle, Christopher A., Mercado, Elvira, Nagoshi, Ying, Newsom, Kimberly, Wright, Ashleigh, Rosenberg, Eric I., Starostik, Petr, Clare-Salzler, Michael J., Schmidt, Siegfried O., Fillingim, Roger B., Johnson, Julie A., Cavallari, Larisa H.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6650382/
https://ncbi.nlm.nih.gov/pubmed/30670877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41436-018-0431-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars